Tamoxifen integromics and personalized medicine: Dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment

OMICS A Journal of Integrative Biology

Volumn 18, Issue 1, 2014, Pages 15-33

  Dimitrakopoulou, Konstantina ^a   Dimitrakopoulos, Georgios N ^a,b   Sgarbas, Kyriakos N ^b   Bezerianos, Anastasios ^a,c  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTOME;

ALGORITHM; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE; HUMAN; IMMUNOMODULATION; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN INTERACTION; TUMOR XENOGRAFT;

ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CELL CYCLE; FEMALE; GENE REGULATORY NETWORKS; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN INTERACTION MAPPING; TAMOXIFEN; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84893041759     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2013.0055     Document Type: Article

References (76)

1. Ahn J, Yoon Y, Park C, Shin E, and Park S. (2011). Integrative gene network construction for predicting a set of complementary prostate cancer genes. Bioinformatics 27, 1846-1853
2. Antman E, Weiss S, and Loscalzo J. (2012). Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdiscip Rev Syst Biol Med 4, 367-383
3. Akman BH, Can T, and Erson-Bensan AE. (2012). Estrogeninduced upregulation and 3'-UTR shortening of CDC6. Nucleic Acids Res 40, 10679-10688
4. Becker M, Sommer A, Krätzschmar JR, Seidel H, Pohlenz HD, and Fichtner I. (2005). Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 4, 151-168
5. Berger SI, and Iyengar R. (2009). Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472
6. Behjati S, and Frank MH. (2009). The effects of tamoxifen on immunity. Curr Med Chem 16, 3076-3080
7. Bertucci F, Finetti P, Cervera N, et al. (2006). Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66, 4636-4644
8. Bonte D, Lindvall C, Liu H, Dykema K, Furge K, and Weinreich M. (2008). Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia 10, 920-931
9. Chen D, Landis-Piwowar KR, Chen MS, and Dou QP. (2007). Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res 9, R80
10. Chen L, Xuan J, Riggins RB, Wang Y, and Clarke R. (2013). Identifying protein interaction subnetworks by a bagging Markov random field-based method. Nucleic Acids Res 41, e42
11. Chuang HY, Lee E, Liu YT, Lee D, and Ideker T. (2007). Network-based classification of breast cancer metastasis. Mol Syst Biol 3, 140
12. Couch RD, and Mott BT. (2012). Personalized medicine: Changing the paradigm of drug development. Methods Mol Biol 823, 367-378
13. Cun Y, and Fröhlich HF. (2012). Prognostic gene signatures for patient stratification in breast cancer: Accuracy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein interactions. BMC Bioinformat 13, 69
14. Dimitrakopoulou K, Dimitrakopoulos G, Zacharaki EI, Maraziotis IA, Sgarbas K, and Bezerianos A. (2012). Revealing the dynamic modularity of composite biological networks in breast cancer treatment. Conf Proc IEEE Eng Med Biol Soc 2012, 5432-5436
15. Duffy MJ, O'Donovan N, and Crown J. (2011). Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 37, 151-159
16. Feng C, Chen L, Li W, et al. (2012). Identifying grade/stagerelated active modules in human co-regulatory networks: A case study for breast cancer. OMICS 16, 681-689
17. Fredlund E, Staaf J, Rantala JK, Kallioniemi O, Borg A, and Ringnér M. (2012). The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res 14, R113
18. Fröhlich H. (2011). Network based consensus gene signatures for biomarker discovery in breast cancer. PLoS One 6, e25364
19. Gentleman RC, Carey VJ, Bates DM, et al. (2004). Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5, R80
20. Georgii E, Dietmann S, Uno T, Pagel P, and Tsuda K. (2009). Enumeration of condition-dependent dense modules in protein interaction networks. Bioinformatics 25, 933-940
21. Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, and Williams GH. (2002). Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 50, 373-377
22. Hecker M, Lambeck S, Toepfer S, van Someren E, and Guthke R. (2009). Gene regulatory network inference: Data integration in dynamic models-A review. BioSystems 96, 86-103
23. Hegde SR, Manimaran P, and Mande SC. (2008). Dynamic changes in protein functional linkage networks revealed by integration with gene expression data. PLoS Comput Biol 4, e1000237
24. Honma N, Horii R, Iwase T, et al. (2008).Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26, 3727-3734
25. Horner-Glister E, Maleki-Dizaji M, Guerin CJ, Johnson SM, Styles J, and White IN. (2005). Influence of oestradiol and tamoxifen on oestrogen receptors-Alpha and-beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells. J Mol Endocrinol 35, 421-432
26. Huang DW, Sherman BT, and Lempicki RA. (2009). Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc 4, 44-57
27. Jahid MJ, and Ruan J. (2012). A Steiner tree-based method for biomarker discovery and classification in breast cancer metastasis. BMC Genom 13, S8
28. Javierre BM, Rodriguez-Ubreva J, Al-Shahrour F, et al. (2011). Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells. Mol Cancer Res 9, 1139-1151
29. Johansson I, Aaltonen KE, Ebbesson A, et al. (2012). Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. Genes Chromosomes Cancer 51, 375-383
30. Jørgensen JT. (2011). A challenging drug development process in the era of personalized medicine. Drug Discov Today 16, 891-897
31. Kang JM, Park S, Kim SJ, et al. (2012). CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-b signaling. Oncogene 31, 5123-5131
32. Komurov K, Tseng JT, Muller M, et al. (2012). The glucosedeprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 8, 596
33. Kuo CC, Liu JF, Shiah HS, Ma LC, and Chang JY. (2007). Tamoxifen accelerates proteasomal degradation of O6-methylguanine DNA methyltransferase in human cancer cells. Int J Cancer 121, 2293-2300
34. Labib K, Tercero JA, and Diffley JF. (2000). Uninterrupted MCM2-7 function required for DNA replication fork progression. Science 288, 1643-1647
35. Li J, Lenferink AE, Deng Y, et al. (2010). Identification of highquality cancer prognostic markers and metastasis network modules. Nat Commun 1, 34
36. Lord CJ, and Ashworth A. (2012). The DNA damage response and cancer therapy. Nature 481, 287-294
37. Lu WJ, Desta Z, and Flockhart DA. (2012). Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat 131, 473-481
38. Lu WJ, Xu C, Pei Z, Mayhoub AS, Cushman M, and Flockhart DA. (2012). The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat 133, 99-109
39. Ma Z, Gibson SL, Byrne MA, Zhang J, White MF, and Shaw LM. (2006). Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol Cell Biol 26, 9338-9351
40. Maraziotis IA, Dimitrakopoulou K, and Bezerianos A. (2007). Growing functional modules from a seed protein via integration of protein interaction and gene expression data. BMC Bioinformat 8, 408
41. Maraziotis IA, Dimitrakopoulou K, and Bezerianos A. (2008). An in silico method for detecting overlapping functional modules from composite biological networks. BMC Syst Biol 2, 93
42. Matsuyoshi S, Shimada K, Nakamura M, Ishida E, and Konishi N. (2006). FADD phosphorylation is critical for cell cycle regulation in breast cancer cells. Br J Cancer 94, 532-539
43. McGovern SL, Qi Y, Pusztai L, Symmans WF, and Buchholz TA. (2012). Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res 14, R72
44. Mendes-Pereira AM, Sims D, Dexter T, et al. (2012). Genomewide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 109, 2730-2735
45. Meyer UA, Zanger UM, and Schwab M. (2013). Omics and drug response. Annu Rev Pharmacol Toxicol 53, 475-502
46. Mihalik Á, and Csermely P. (2011). Heat shock partially dissociates the overlapping modules of the yeast protein-protein interaction network: A systems level model of adaptation. PLoS Comput Biol 7, e1002187
47. Mor G, Kohen F, Garcia-Velasco J, et al. (2000). Regulation of fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 73, 185-194
48. Mora A, and Donaldson IM. (2012). Effects of protein interaction data integration, representation and reliability on the use of network properties for drug target prediction. BMC Bioinformat 13, 294
49. Moreira PI, Custó dio J, Moreno A, Oliveira CR, and Santos MS. (2006). Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J Biol Chem 281, 10143-10152
50. Mutarelli M, Cicatiello L, Ferraro L, et al. (2008). Time-course analysis of genome-wide gene expression data from hormoneresponsive human breast cancer cells. BMC Bioinformat 9, S12
51. Niida A, Smith AD, Imoto S, Aburatani H, Zhang MQ, and Akiyama T. (2009). Gene set-based module discovery in the breast cancer transcriptome. BMC Bioinformat 10, 71
52. Pinkert S, Schultz J, and Reichardt J. (2010). Protein interaction networks-More than mere modules. PLoS Comput Biol 6, e1000659
53. Pollok S, Bauerschmidt C, Sänger J, Nasheuer HP, and Grosse F. (2007). Human Cdc45 is a proliferation-Associated antigen. FEBS J 274, 3669-3684
54. Rossin EJ, Lage K, Raychaudhuri S, et al. (2011). Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 7, e1001273
55. Salazar MD, Ratnam M, Patki M, et al. (2011). During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor a1 apoprotein. Breast Cancer Res 13, R18
56. Scardoni G, Petterlini M, and Laudanna C. (2009). Analyzing biological network parameters with CentiScaPe. Bioinformatics 25, 2857-2859
57. Schwab M, and Schaeffeler E. (2012). Pharmacogenomics: A key component of personalized therapy. Genome Med 4, 93
58. Shannon P, Markiel A, Ozier O, et al. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504
59. Sharan R, Ulitsky I, and Shamir R. (2007). Network-based prediction of protein function. Mol Syst Biol 3, 88
60. Shih YK, and Parthasarathy S. (2012). Identifying functional modules in interaction networks through overlapping Markov clustering. Bioinformatics 28, i473-i479
61. Taylor IW, Linding R, Warde-Farley D, et al. (2009). Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 27, 199-204
62. Taylor KJ, Sims AH, Liang L, et al. (2010). Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-Treated patients with breast cancer. Breast Cancer Res 12, R39
63. Ulitsky I, and Shamir R. (2009). Identifying functional modules using expression profiles and confidence-scored protein interactions. Bioinformatics 25, 1158-1164
64. vanVliet MH, Klijn CN, Wessels LF, and Reinders MJ. (2007). Module-based outcome prediction using breast cancer compendia. PLoS One 2, e1047
65. Wakefield A, Soukupova J, Montagne A, et al. (2013). Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. Cancer Res 73, 745-755
66. WangJ, Chen G, Li M, and Pan,Y. (2011). Integration of breast cancer gene signatures based on graph centrality. BMC Syst Biol 5, S10
67. Wang X, Wang Z, and Ye J. (2011). HKC: An algorithm to predict protein complexes in protein-protein interaction networks. J Biomed Biotechnol 2011, 480294
68. Warsow G, Greber B, Falk SS, et al. (2010). ExprEssence-Revealing the essence of differential experimental data in the context of an interaction/regulation net-work. BMC Syst Biol 4, 164
69. Wu C, Zhu J, and Zhang X. (2012). Integrating gene expression and protein-protein interaction network to prioritize cancerassociated genes. BMC Bioinformat 13, 182
70. Wu G, and Stein L. (2012). A network module-based method for identifying cancer prognostic signatures. Genome Biol 13, R112
71. Wu Z, Zhao X, and Chen L. (2009). Identifying responsive functional modules from protein-protein interaction network. Mol Cells 27, 271-277
72. Wu X, Subramaniam M, Grygo SB, et al. (2011). Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res 13, R27
73. Zeng T, Wang R, and Chen L. (2012). Module network rewiring in response to therapy. IEEE 6th International Conference on Systems Biology (ISB), 18-20 Aug 2012, 197-202
74. Zhang J, Xiang Y, Ding L, et al. (2010). Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia. BMC Bioinformat 11, S5
75. Zhao S, and Iyengar R. (2012). Systems pharmacology: Network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 52, 505-521
76. Zhou C, Zhong Q, Rhodes LV, et al. (2012). Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res 14, R45